|Does not negate estrogen’s effects on lipids and modestly improves cholesterol ||Adversely affects lipids and negates estrogen’s beneficial influence |
|Has an antihypertensive effect ||Causes edema and fluid retention; increases risk of coronary heart disease, stroke and venous thromboembolism |
|Improves sleep and has a calming effect ||Causes insomnia and anxiety |
|Prevents postpartum depression ||Causes depression |
|Has no effect upon the liver,||Contraindicated in liver dysfunction |
|Used in the luteal phase to help a woman become pregnant  to maintain a pregnancy ||Contraindicated in pregnancy |
|Protects against breast cancer ||Increases risk of breast cancer |
|Stimulates osteoblasts, which help to build bone ||Reduces bone density |
|Works with pancreas to increase the release of insulin ||Causes deterioration of glucose tolerance |
 The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199-208.
 Kristiansson P, Wang JX. Reproductive hormones and blood pressure during pregnancy. Hum Reprod. 2001;16(1):13-17.
 PDR Staff. 2016 Physicians’ Desk Reference, 70th Edition. PDR Network; 2015.
 Schüssler P, Kluge M, Yassouridis A, et al. Progesterone reduces wakefulness in sleep EEG and has no effect on cognition in healthy postmenopausal women. Psychoneuroendocrinology. 2008;33(8):1124-31.
 Provera (medroxyprogesterone acetate) [prescribing information]. New York, NY: Pfizer; May 2015.
 Dalton K. Succesful prophylactic progesterone for idiopathic postnatal depression. Int. J. Prenatal and Perinatal Studies. 1989:323–327.
 Bolaji II, Grimes H, Mortimer G, Tallon DF, Fottrell PF, O’dwyer EM. Low-dose progesterone therapy in oestrogenised postmenopausal women: effects on plasma lipids, lipoproteins and liver function parameters. Eur J Obstet Gynecol Reprod Biol. 1993;48(1):61-8.
 Darj E, Axelsson O, Carlström K, Nilsson S, Von schoultz B. Liver metabolism during treatment with estradiol and natural progesterone. Gynecol Endocrinol. 1993;7(2):111-4.
 Cometti B. Pharmaceutical and clinical development of a novel progesterone formulation. Acta Obstet Gynecol Scand. 2015;94 Suppl 161:28-37.
 Goodman LS, Gilman AG, Hardman JG et al. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 12th Edition. McGraw-Hill Book Company Limited; 2011.
 Lambrinoudaki I. Progestogens in postmenopausal hormone therapy and the risk of breast cancer. Maturitas. 2014;77(4):311-7.
 Compston JE. Sex steroids and bone. Physiol Rev. 2001;81(1):419-447.
 Cundy T, Farquhar CM, Cornish J, Reid IR. Short-term effects of high dose oral medroxyprogesterone acetate on bone density in premenopausal women. J Clin Endocrinol Metab. 1996;81(3):1014-7.
 Fraser IS. Estrogens and Progestogens in Clinical Practice. London; Churchill Livingstone; 1998.